Taiwan Liposome Co., Ltd.

Student models will be joined on the runway by cancer patients helped by The Verma Foundation NEW YORK, April 8, 2024 /PRNewswire/ -- LIM College today announced that the creations of notable independent New York fashion designers—with a focus on those of color who design for all gender representations, sizes and ages—will be highlighted on the runway at the college's student-produced LIM Fashion Show, April 19 at 6 p.m. at The Glasshouse, 660 12th Ave. Continue Reading LIM College's Fashion Show April 19 will feature independent NYC designers who focus on diversity and inclusivity. Located in New York City, LIM College is focused exclusively on the business of fashion and lifestyle. Each year, LIM provides students with a hands-on educational experience planning and producing a professional-level fashion show. While they do not design the apparel featured in the show, students are responsible for every other aspect of the production including styling, marketing, set design, event planning, and more. Among the featured designers who will be showcased at the event, which is themed Fashion Unleashed: Embracing the Elements, will be Carlton Jones, Cheval , Karl Kani , Adrienne Landau and Melesia Robinson. Carlton Jones, who began his career as a stylist working with Queen Latifah, went on to become a fashion correspondent on daytime talk shows and a fashion editor and style director, landing his work on the pages of Vogue, GQ, Rolling Stone, Essence and other publications. Jones now expresses his love of style and fashion through his eponymous resort-inspired collection, utilizing his experiences dressing a variety of body types, ranging from Halle Berry and Erykah Badu to Lenny Kravitz and Michelle Obama. Cheval is the Founder and Chief Inspiration Officer of the She is Cheval footwear line. As a designer on TLC's "Say Yes to the Dress," Cheval (operating then under another name) brought over 10 bridal product lines to market, dressed icons such as Chrissy Teigen and Carrie Underwood, and became one of the most sought-after luxury bridal designers in the world. In 2022, she officially changed her name to Cheval and has launched a non-profit organization, A Girl You Might Know Foundation, that provides resources to protect the interests of young women and creatives during the formative years of their careers. The roots of streetwear trace back to designer, mogul, innovator, creator and visionary Karl Kani. As a youth, Kani created custom baggy jeans and oversized shirts, and he soon had a business on his hands. Recognizing the need to brand himself, Kani emblazoned his name on his pieces. In the early '90s, Kani opened a brick-and-mortar store in Los Angeles and it wasn't long before superstars including Biggie, Michael Jackson, Dave Chappelle, Dominique Wilkins and others were wearing Karl Kani. He was even invited to present his creations at the White House. In 1994, Kani expanded into footwear, with his signature basketball shoes donned on the court by star NBA players. In 2022, Kani introduced a groundbreaking collaboration with the Netflix hit series, Stranger Things, and today, he is relaunching his brand in the U.S. and adding a new fragrance line as well as planning to debut his memoir. Kani's company maintains a commitment to education and mentorship, partnering with Ember Charter Schools, among others. Adrienne Landau's fashion career started when, as an artist, she traded some of her paintings in exchange for a fur coat and some fur scraps. She then began fashioning the material in unique ways, leading to the design sensibility that continues to infuse her work, which incorporates unusual combinations of materials in unique ways. In addition to her work appearing on the covers of Vogue, W, Vanity Fair, InStyle and others, and being seen in television and films, Landau continues to have a strong celebrity following including stars such as Oprah Winfrey, Janet Jackson, Barbra Streisand, Jerry Hall, Sharon Stone, and Patti LaBelle. Recently, in partnership with Meridian Brands, LLC, which signed a long-term licensing agreement with Landau, she launched an expansive new collection including her historically iconic accessories and outerwear updated and enhanced for today. Melesia Robinson is a rare combination of Navy veteran and self-taught couture designer. Her mission is to help modern professional women acquire custom garments that elevate their style and showcase their best assets. After serving in the military, Robinson purchased a sewing machine and started a women's clothing boutique. With various starts and stops over several years, Robinson began creating her own pieces to shoot with fashion photographers and models. Her work has been featured in Vogue, Harper's Bazaar, Elle, Marie Claire and others. She has also participated in numerous shows, including at New York Fashion Week, and she was nominated for fashion designer of the year by ACHI Magazine. In addition to featuring the work of these and other designers, the LIM College Fashion Show will feature student models, who are part of the large contingent of LIM students who produce all aspects of the show including styling, marketing, set design, event planning, and more. Student models will be joined on the runway by cancer patients who have been helped by the Verma Foundation. The foundation provides free cap wigs to those dealing with cancer-related hair loss and was co-founded by Natasha Verma, a cancer survivor and Fox5NY News Anchor who is serving as one of the honorary chairs for the LIM Fashion Show. Additional Honorary Chairs include Elliot Carlyle, Founder of CurrentLY Global and a fashion and jewelry industry consultant; Kirsten Ferguson, Peloton Fitness Instructor; and Emme, American supermodel and founder of the True Beauty Foundation. To date, sponsor and partner organizations for the event include: Alice + Olivia, Nine West/Authentic Brands Group, Boxed Water, Curl Daddy, Empire Beauty Schools, Fashinnovation, Fashion Designers of Latin America, Free People, Kendra Scott, The Lions Talent Management Company, RAREculture, Vera Bradley and the Verma Foundation. Tickets for the LIM Fashion Show can be obtained at: About LIM College Founded in 1939 and located in midtown Manhattan, LIM College is focused on the global business of fashion and lifestyle. Offering master's, bachelor's and associate degree programs, LIM prepares students for career success via an immersive approach grounded in real-world experience and "learning by doing" through required internships. LIM College's commitment to excellence in business education ensures graduates are sought after by a wide range of employers, as evidenced by a Career Outcomes Rate of 96% for the Class of 2022. Alumni excel throughout all areas of fashion and lifestyle and have gone on to work for companies such as Chanel, Gucci, Alexander McQueen, Ross Stores, Ulta Beauty, Google, Microsoft, Saks Fifth Avenue, Walmart, Macy's, and the National Football League. Contact: Anne Roman [email protected] 419.708.5171 Meredith Finnin [email protected] 646.218.2156 SOURCE LIM COLLEGE

DUBLIN--( BUSINESS WIRE )--The "Modified Release Neurology Therapeutics" report has been added to ResearchAndMarkets.com's offering. Large pharmaceutical and biotechnology companies are increasingly pursuing in-licensing to offset lower than expected drug development productivity and surging research costs. Data mining technologies, combined with data from genomics, combinational chemistry and outcome-based medicine, provide opportunities to search for new patterns. By using hypertext type tools, companies are finding it possible to build knowledge bases where scientists can link data and ideas to generate insights into new relationships between population groups, diseases, and treatment. For long-acting formulations of Injectable drugs, development collaborations typically follow one of two business models. The majority of projects/products are marked by a contractual relationship between the formulation IP developer/holder and the drug developer. The second notable business model is more ambitious and is defined by formulation IP companies that develop long-acting formulations in-house before licensing the marketing rights to a partner, typically in late stage clinical development or after filing an NDA. This is a more powerful financial model, but has a higher level of risk and requires adequate capitalization to finance drug development into or up to Phase 3 trials. The report provides developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, opportunities for injection devices that are designed for patient self-administration. Provider organization business managers, healthcare administrators and investors will also benefit from this study. The study: Analyzes and evaluates modified release neurology therapeutics products and assesses the market potential for existing and probable future products Analyzes product strategies, technologies and market development issues Provides detailed analysis of neurology market segments, market demographics, and therapeutic strategies Profiles market sector companies, their product development activities, business strategies, and corporate alliances and affiliations Evaluates the impact of economic, technology, and regulatory factors on neurology drug markets As patients live longer and the prevalence and incidence of chronic ailments increase across the general population, drug developers and their delivery device partners are adapting to address what will become a significant market opportunity. Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less. A number of companies - contract research organizations or CROs, - offer a variety of pharmaceutical services to drug developers and marketers, including drug formulation development, niche manufacturing, and pre-clinical evaluation. Formulation development services range from new compounds to modifications of existing products. Some companies offer product modification and line extension services for marketed products facing patent expiration or for products that can benefit from formulation improvements. Modifications of existing products to incorporate improved product characteristics can include enhancement of stability, absorption profiles, taste, and appearance. Product line extensions can include controlled release formulations, as well as new dosage strengths. Product modifications and line extensions can create the opportunity to target new patient populations and improve patient acceptance of the product. Other formulation services offered on a contract basis include investigation of impurities, contaminants and degradation, the updating of mature products to meet current regulatory standards and laboratory validation services. Key Topics Covered: The Neurological Drug Market Dynamics The Trend Toward Self-Administration Route of Administration Innovation in Drug Formulation Neurological Drugs and As-supplied Packaging Human Engineering/Ergonomics Delivering Neurological Drugs via Injection Primary Packaging Innovation in Injectable Device Designs Drug Delivery Device Selection Issues Therapeutic Demand Drivers Key Market Factors MR Neurological Product Analysis Proprietary Formulation Technology ChroniJect (Oakwood Laboratories/PharmaSophia) CriticalMix (Critical Pharmaceuticals) Depofoam (Pacira) FluidCrystal (Camarus) LinkeRx (Alkermes) Medisorb (Alkermes) Medusa (Recipharm/Avadel) Nanocrystals (Alkermes) Optisomes (Talon/Spectrum) PolyActive (Octoplus) Q-Sphera (Midatech Pharma) SABER/SAIB (DURECT) SynBiosys (Innocore) TransCon (Ascendis) Physical Process Control Methods Supercritical Fluid SCF for Nanoparticle Formulations Formulplex (Supercritical Solutions) Ferro SCF extraction of emulsions (SFEE) Stability Administration Factors Therapeutic Market Sectors Schizophrenia Bipolar Disorder Market Sector Analysis and Forecasts Key Market Factors Economic Factors Technology Factors Regulatory Factors Risk Factors Forecasts and Market Data Company Profiles Alkermes Amylin AntriaBio Ascendis Pharma AstraZeneca Aurobundo Avadel Biomarin Camurus Critical Pharmaceuticals DURECT Eli Lilly Enzon Ipsen Janssen NanOlogy Novartis Oakwood Laboratories/PharmaSophia OctoPlus Pacira PhaseBio Pharmaceuticals Recipharm AB Roche Sanofi Taiwan Liposome Company Xbrane Bipharma For more information about this report visit https://www.researchandmarkets.com/r/z14n0x About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN, Feb. 14, 2024 /PRNewswire/ -- The "Modified Release Neurology Therapeutics" report has been added to ResearchAndMarkets.com's offering. Large pharmaceutical and biotechnology companies are increasingly pursuing in-licensing to offset lower than expected drug development productivity and surging research costs. Data mining technologies, combined with data from genomics, combinational chemistry and outcome-based medicine, provide opportunities to search for new patterns. By using hypertext type tools, companies are finding it possible to build knowledge bases where scientists can link data and ideas to generate insights into new relationships between population groups, diseases, and treatment. For long-acting formulations of Injectable drugs, development collaborations typically follow one of two business models. The majority of projects/products are marked by a contractual relationship between the formulation IP developer/holder and the drug developer. The second notable business model is more ambitious and is defined by formulation IP companies that develop long-acting formulations in-house before licensing the marketing rights to a partner, typically in late stage clinical development or after filing an NDA. This is a more powerful financial model, but has a higher level of risk and requires adequate capitalization to finance drug development into or up to Phase 3 trials. The report provides developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, opportunities for injection devices that are designed for patient self-administration. Provider organization business managers, healthcare administrators and investors will also benefit from this study. The study: Analyzes and evaluates modified release neurology therapeutics products and assesses the market potential for existing and probable future products Analyzes product strategies, technologies and market development issues Provides detailed analysis of neurology market segments, market demographics, and therapeutic strategies Profiles market sector companies, their product development activities, business strategies, and corporate alliances and affiliations Evaluates the impact of economic, technology, and regulatory factors on neurology drug markets As patients live longer and the prevalence and incidence of chronic ailments increase across the general population, drug developers and their delivery device partners are adapting to address what will become a significant market opportunity. Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less. A number of companies - contract research organizations or CROs, - offer a variety of pharmaceutical services to drug developers and marketers, including drug formulation development, niche manufacturing, and pre-clinical evaluation. Formulation development services range from new compounds to modifications of existing products. Some companies offer product modification and line extension services for marketed products facing patent expiration or for products that can benefit from formulation improvements. Modifications of existing products to incorporate improved product characteristics can include enhancement of stability, absorption profiles, taste, and appearance. Product line extensions can include controlled release formulations, as well as new dosage strengths. Product modifications and line extensions can create the opportunity to target new patient populations and improve patient acceptance of the product. Other formulation services offered on a contract basis include investigation of impurities, contaminants and degradation, the updating of mature products to meet current regulatory standards and laboratory validation services. Key Topics Covered: The Neurological Drug Market Dynamics The Trend Toward Self-Administration Route of Administration Innovation in Drug Formulation Neurological Drugs and As-supplied Packaging Human Engineering/Ergonomics Delivering Neurological Drugs via Injection Primary Packaging Innovation in Injectable Device Designs Drug Delivery Device Selection Issues Therapeutic Demand Drivers Key Market Factors MR Neurological Product Analysis Proprietary Formulation Technology ChroniJect (Oakwood Laboratories/PharmaSophia) CriticalMix (Critical Pharmaceuticals) Depofoam (Pacira) FluidCrystal (Camarus) LinkeRx (Alkermes) Medisorb (Alkermes) Medusa (Recipharm/Avadel) Nanocrystals (Alkermes) Optisomes (Talon/Spectrum) PolyActive (Octoplus) Q-Sphera (Midatech Pharma) SABER/SAIB (DURECT) SynBiosys (Innocore) TransCon (Ascendis) Physical Process Control Methods Supercritical Fluid SCF for Nanoparticle Formulations Formulplex (Supercritical Solutions) Ferro SCF extraction of emulsions (SFEE) Stability Administration Factors Therapeutic Market Sectors Schizophrenia Bipolar Disorder Market Sector Analysis and Forecasts Key Market Factors Economic Factors Technology Factors Regulatory Factors Risk Factors Forecasts and Market Data Company Profiles Alkermes Amylin AntriaBio Ascendis Pharma AstraZeneca Aurobundo Avadel Biomarin Camurus Critical Pharmaceuticals DURECT Eli Lilly Enzon Ipsen Janssen NanOlogy Novartis Oakwood Laboratories/PharmaSophia OctoPlus Pacira PhaseBio Pharmaceuticals Recipharm AB Roche Sanofi Taiwan Liposome Company Xbrane Bipharma For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets